SynthesisPloS one2025
Significance of the cribriform pattern in predicting the prognosis of lung adenocarcinoma patients: A systematic review and meta-analysis.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA number of studies have shown that various histological subtypes of lung adenocarcinoma have different clinical prognoses, but the cribriform pattern, as a unique histological subtype, plays an important role in the prognosis of patients with lung adenocarcinoma.
objectiveIn this meta-analysis, we evaluated the role of the cribriform pattern in the overall survival of patients with lung adenocarcinoma, which may provide valuable information for the treatment of patients with lung adenocarcinoma. This also provides an important basis for dividing the cribriform pattern into a new histological subtype and classifying it.
methodsWe searched the literature from the PubMed, Embase, Cochrane and Web of Science online databases; extracted the data and characteristics of each study; and extracted and calculated hazard ratios (HRs) with 95% confidence intervals (CIs) to evaluate the impact of the cribriform pattern on the prognosis of patients with lung adenocarcinoma.
resultsA total of 10 articles were included in the study according to the preset criteria, with a total of 5487 research subjects. The hazard ratio for the relationship between the cribriform pattern and the overall survival rate of patients with lung adenocarcinoma was 2.05 (95% CI: 1.76-2.39). The prognosis of patients with positive spread through air spaces in the cribriform pattern was significantly worse than that of patients with negative spread through air spaces in the cribriform pattern, with a hazard ratio of 2.58 (95% CI: 1.84-3.62). There was a significant difference in prognosis between patients with the cribriform pattern and those with low-grade and intermediate-grade lung adenocarcinoma, but there was no significant difference in prognosis between patients with the cribriform pattern and those with high-grade lung adenocarcinoma, with hazard ratios of 2.12 (95% CI: 1.12-4.00), 7.70 (95% CI: 2.15-36.20) and 0.96 (95% CI: 0.54-2.40), respectively. Therefore, the cribriform pattern should be used as a histological subtype of high-grade tumors, thus influencing the postoperative prognosis of patients with lung adenocarcinoma.
conclusionThe presence of the cribriform pattern is an independent risk factor for postoperative overall survival in patients with lung adenocarcinoma. The cribriform pattern should be considered a new histological subtype of lung adenocarcinoma and classified with solid carcinoma and micropapillary adenocarcinoma as high-grade tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.